GRI Bio announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. Patient dosing is expected imminently. Interim data from the Phase 2a biomarker study is expected in the first half of 2024 and topline results are expected in the second half of 2024. “The start of enrollment marks another important step forward for GRI as we continue to execute our clinical development plans for our lead program, GRI-0621. We are pleased to meet this significant milestone and remain focused on the successful execution of this Phase 2a study. With the progress made to date and the start of patient dosing expected imminently, we are poised for an exciting 2024 and look forward to unlocking the potential of GRI-0621 for the treatment of fibrotic indications, starting with IPF,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRI:
- GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
- GRI Bio announces FDA clearance of IND for GRI-0621
- GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
- GRI Bio reports net less $11M for nine months ended September 30
- GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update